Randomised controlled trials (RCTs) have long been considered the gold standard of
medical evidence. In relation to cannabis based medicinal products (CBMPs), this focus on …

Background Although pre-clinical experiments associate cannabinoids with reduced
depressive symptoms, there is a paucity of clinical evidence. This study aims to analyze the …

Insomnia or difficulty falling and or staying asleep is experienced by up to 30% of the
general population. This randomised crossover double‐blind placebo‐controlled 6‐week …

Purpose During the treatment of cancer, 18% of patients use cannabis for symptom
management. Anxiety, depression, and sleep disturbances are common symptoms in …

Introduction: There is a growing body of literature supporting the efficacy of cannabis-based
medicinal products (CBMPs). Despite an increase in prescribing globally, there is a paucity …

Inadequate sleep is a global health concern. Sleep is multidimensional and complex; new
multi-ingredient agents are needed. This study assessed the comparative effects of two multi …

Sleep is an essential biological phase of our daily life cycle and is necessary for maintaining
homeostasis, alertness, metabolism, cognition, and other key functions across the animal …

Sleep disturbances are often cited as a primary reason for medicinal cannabis use, and
there is increasing clinical interest in the therapeutic potential of cannabinoids in treating …

The present study sought to determine the effects of cannabinol (CBN) alone and in
combination with cannabidiol (CBD) on sleep quality. This was a double-blind, randomized …

Introduction Oral medicinal cannabis (MC) has been increasingly prescribed for a wide
range of clinical conditions since 2016. Despite an exponential rise in prescriptions and …